The key vendors in the Global Epilepsy Market 2014-2018 are GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
London, 28 October 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Epilepsy Market 2014-2018. One key trend in this market is the reformulation of marketed drugs. Reformulated drugs, usually, have better tolerability and better dosing schedules than the original drugs. This increases the market acceptance of such drugs, driving their market revenue. The Global Epilepsy market is expected to post a CAGR of 5.06 percent during the period 2013-2018.
Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. It is characterized by repeated occurrence of generalized or focal seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.
“Market strategization of major vendors to penetrate countries in the APAC region and increasing healthcare reforms are expected to change the treatment regimen for epilepsy,” says Faisal Ghaus, Vice President of TechNavio Research.
“Japan is anticipated to experience a major shift in trend toward second-generation drugs because of the recent launch of these drugs in the Japanese market.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
